Gerald Dorn II discovered fundamental mechanisms regulating mitochondrial homeostasis, programmed elimination and metabolic remodeling in cardiac and neurological disease. Using conditional gene manipulation, he uncovered multiple pathological roles for Nix and Bnip3 in cardiac decompensation: activating the intrinsic (mitochondrial) apoptotic pathway, promoting mitophagy and stimulating mitochondrial calcium import from the endo/sarcoplasmic reticulum (ER/SR).
Dorn’s interrogation of mitochondrial tethering and fusion revised fundamental concepts of mitochondrial quality control and metabolic transitioning. He discovered dual, mutually exclusive functioning of Mfn2 as a mitochondrial fusion protein and mitochondrial receptor for Parkin, establishing Mfn2 phosphorylation as a critical determinant of individual mitochondrial fate. He then demonstrated that this mechanism also mediates generalized mitochondrial turnover essential to the normal perinatal cardiac switch in metabolic substrate use from carbohydrates to fatty acids.
Dorn established that mitofusins transition between fusion-constrained and fusion-permissive conformations. He engineered cell-permeable peptides and small molecule peptidomimetics that destabilize the fusion-constrained conformation, thus promoting mitochondrial fusion. Dorn has used these first-in-class mitofusin activators to delay and reverse neurodegeneration in experimental CMT2A and ALS.
Gerald Dorn II discovered fundamental mechanisms regulating mitochondrial homeostasis, programmed elimination and metabolic remodeling in cardiac and neurological disease. Using conditional gene manipulation, he uncovered multiple pathological roles for Nix and Bnip3 in cardiac decompensation: activating the intrinsic (mitochondrial) apoptotic pathway, promoting mitophagy and stimulating mitochondrial calcium import from the endo/sarcoplasmic reticulum (ER/SR).
Dorn’s interrogation of mitochondrial tethering and fusion revised fundamental concepts of mitochondrial quality control and metabolic transitioning. He discovered dual, mutually exclusive functioning of Mfn2 as a mitochondrial fusion protein and mitochondrial receptor for Parkin, establishing Mfn2 phosphorylation as a critical determinant of individual mitochondrial fate. He then demonstrated that this mechanism also mediates generalized mitochondrial turnover essential to the normal perinatal cardiac switch in metabolic substrate use from carbohydrates to fatty acids.
Dorn established that mitofusins transition between fusion-constrained and fusion-permissive conformations. He engineered cell-permeable peptides and small molecule peptidomimetics that destabilize the fusion-constrained conformation, thus promoting mitochondrial fusion. Dorn has used these first-in-class mitofusin activators to delay and reverse neurodegeneration in experimental CMT2A and ALS.